Department of Cadre's Ward, The 904th Hospital of Joint Logistic Support Force, Wuxi, China.
Department of Neurosurgery, The 904 Hospital of Joint Logistic Support Force, Wuxi, China.
Medicine (Baltimore). 2023 Sep 22;102(38):e35190. doi: 10.1097/MD.0000000000035190.
Traumatic brain injury (TBI) is a significant contributor to global mortality and impairment. Experimental data has shown the advantages of remote ischemic preconditioning (RIPC) in treating brain injury, however, there is a lack of evidence-based medicine regarding its clinical effectiveness and safety.
In this study, we investigated whether RIPC could enhance outcomes in patients with severe TBI. Between January 2019 and December 2022, a comprehensive assessment was conducted on 392 individuals with severe TBI. Out of these, 304 patients were initially included and randomly assigned to receive either RIPC treatment (n = 153) or a control treatment (n = 151). The main measures of results included Glasgow Outcome Scale scores at 6 months, the occurrence of cerebral infarction during hospitalization, mortality rate within 30 days, levels of neuron-specific enolase and S-100β, any adverse effects, expenses incurred during hospitalization, and duration of hospital stay.
The 2 groups did not show any statistically significant differences in baseline clinical data. The Glasgow Outcome Scale scores at 6 months in the RIPC group showed significant improvement when compared with the control group. Additionally, the application of RIPC therapy can reduce the concentrations of neuron-specific enolase and S-100β. There was no notable distinction observed between the 2 groups regarding the adverse reactions of RIPC-induced objective indications of tissue or neurovascular harm. In the RIPC group, there was a significant reduction in both the duration of hospital stays and the expenses associated with hospitalization.
The results of this study suggest that RIPC has the potential to enhance clinical outcomes, mitigate nerve damage, and reduce both hospital expenses and length of stay in patients with severe TBI. The use of RIPC is a reliable and efficient method for managing severe TBI.
创伤性脑损伤(TBI)是全球死亡率和致残率的主要原因。实验数据表明,远程缺血预处理(RIPC)在治疗脑损伤方面具有优势,然而,其临床疗效和安全性缺乏循证医学证据。
在这项研究中,我们研究了 RIPC 是否可以改善严重 TBI 患者的预后。2019 年 1 月至 2022 年 12 月,对 392 名严重 TBI 患者进行了全面评估。其中,304 名患者最初纳入并随机分为 RIPC 治疗组(n = 153)和对照组(n = 151)。主要结果评估指标包括 6 个月时的格拉斯哥结局量表评分、住院期间脑梗死的发生情况、30 天内死亡率、神经元特异性烯醇化酶和 S-100β水平、任何不良反应、住院费用和住院时间。
两组患者的基线临床数据无统计学差异。RIPC 组 6 个月时格拉斯哥结局量表评分较对照组显著改善。此外,RIPC 治疗可降低神经元特异性烯醇化酶和 S-100β水平。两组间 RIPC 引起的组织或神经血管损害的客观指标的不良反应无明显差异。RIPC 组的住院时间和住院费用显著缩短。
本研究结果表明,RIPC 可能改善严重 TBI 患者的临床预后,减轻神经损伤,降低住院费用和住院时间。RIPC 是治疗严重 TBI 的可靠有效的方法。